$UPXI

UPEXI, INC. (UPXI): Entry into a Material Definitive Agreement

UPEXI, INC. (UPXI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 upxi_ex101.htm ADVISORY SERVICES AGREEMENT upxi_ex101.htm EXHIBIT 10.1 ADVISORY SERVICES AGREEMENT This ADVISORY SERVICES AGREEMENT (this “ Agreement ”), effective June 22, 2026 (the “ Effective Date ”), is entered into by and between Upexi, Inc. (the “ Company ”), and

Original reporting
Published Jun 25, 2026, 8:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 25, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$UPXI
Neutral
medium confidence
Mentioned
$UPXI
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$UPXINeutralLow
01

Why it matters

The agreement sets a three-year term with potential renewal, independent-contractor status, and advisory fees paid in advisory fee shares subject to a 9.99% beneficial ownership share cap; excess fees convert to cash. It also includes registration rights for resale of issued advisory fee shares.

02

Market read

This is a primary disclosure of a new equity-compensation advisory arrangement; the tradable risk is potential future dilution and resale overhang, but the excerpt lacks fee size and issuance schedule.

03

What to watch

Traders may be over-weighting dilution risk without the missing Schedule B fee amounts and issuance timing; the registration-rights clause could matter more than the headline 'material agreement' label.

Relevance 6/10Novelty 4/10Timing: after-hours/filing today (8-K filed June 25, 2026)

Background

The 8-K reports Item 1.01 (material definitive agreement) and Item 3.02 (unregistered sales of equity securities) tied to an Advisory Services Agreement.

Company-level read

Ticker impact

$UPXINeutralMedium confidence
Context

Upexi entered a material definitive advisory agreement effective June 22, 2026, with fees paid via advisory fee shares or cash.

Expected impact

Likely limited near-term impact; any effect would come from expectations of future share issuance/registration rather than immediate fundamentals.

Evidence & confidence

The filing is primary and company-specific, but it provides no deal size, fee schedule, or immediate operational change in the excerpt; the main tradable angle is potential dilution/registration over time.

Market effects

Minimal; this is an individual-company corporate/financing-advisory arrangement rather than a sector-wide regulatory or product catalyst.

None indicated.

None indicated.

Counterpoint

Equity-based advisor compensation may be routine for small caps and could be largely offset by cash payments if the 9.99% share cap is approached.

Key entities

  • Upexi, Inc.

    Company entering the advisory agreement and issuing/arranging advisory fee compensation.

  • Hivemind Capital Partners, LLC

    Advisor appointed to provide advisory and consulting services; receives advisory fee shares/cash.

Related articles

$UPXIMed

Upexi Partners with Blueprint to Stake Solana Treasury Assets

Upexi, Inc. (NASDAQ: UPXI) said it partnered with Blueprint, an institutional Solana staking/infrastructure affiliate of Hivemind Capital Partners, to stake a portion of its Solana (SOL) holdings using Blueprint’s institutional Solana validator. Upexi said it aims to grow its SOL treasury and support Solana network decentralization; it reported holding over 2 million SOL.

$TEVAMed

Teva Transitions To Direct Listing On NYSE

Teva Pharmaceutical (TEVA) will transition to direct listing on NYSE, continuing to trade on NYSE and TASE. The move is part of its Pivot to Growth strategy. The company reported 40% revenue growth in 2025, with 2026 revenues estimated at $3.7B. TEVA closed Friday at $37.09, up 2.04%, and Monday at $38.72, up 4.39%.

$ASNDMed

Ascendis Unveils $400 Mln Buyback; Regains TransCon Rights From Novo Nordisk

Ascendis Pharma (ASND) authorized a $400M share buyback program and regained exclusive rights to TransCon-based products in metabolic and cardiovascular diseases from Novo Nordisk. The company plans to develop new programs, including TransCon Semaglutide for obesity and type 2 diabetes. In Q2 2026, ASND reported a net profit of €207M, up from a €39M loss a year prior, with revenue increasing to €339.29M from €158.04M.

$PBFHighAI 9/10

PBF Energy Announces Pricing of $500 Million of 0% Exchangeable Notes due 2032

PBF Energy's subsidiary priced $500M in 0% exchangeable notes due 2032, with an option for $50M more. Notes are senior, unsecured, and guaranteed by certain subsidiaries. They can be exchanged for cash, stock, or a mix, with an initial exchange rate of 10.3306 shares per $1,000. The offering is expected to close September 17, 2026, with net proceeds estimated at $485M ($533.6M if the option is fully exercised).

$KDPMedAI 8/10

Keurig Dr Pepper breakup could reveal the stronger business

Keurig Dr Pepper (KDP) plans to split into two publicly traded companies by early 2027. Bank of America (BofA) estimates the beverage division could be worth $31 per share, while the coffee division could be worth $7 per share. BofA maintains a Buy rating on KDP with a $38 price target, citing the potential value unlock from the separation. The beverage business has shown strong growth, with Dr Pepper becoming a key driver. KDP aims to reduce debt to maintain investment-grade ratings before the